Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug interaction between DWC20141 and DWC20142 in healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152

NCT02502721

Healthy

COMPLETED PHASE1

Pharmacokinetics and Safety Between "DWJ1421" and "DWC201903" in Healthy Male Volunteers

NCT04278391

Healthy

COMPLETED PHASE1

Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects

NCT05812404

Drug Drug Interaction

UNKNOWN PHASE1

Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

NCT04328766

Drug-drug Interaction

COMPLETED PHASE1

An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers

NCT05832697

Healthy Subject

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DWC20141

multiple dose of DWC20141

Group Type EXPERIMENTAL

DWC20141

Intervention Type DRUG

Tablet

DWC20142

multiple dose of DWC20142

Group Type EXPERIMENTAL

DWC20142

Intervention Type DRUG

Tablet

DWC20141+DWC20142

multiple dose of DWC20141 and DWC20142

Group Type EXPERIMENTAL

DWC20141, DWC20142

Intervention Type DRUG

Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DWC20141

Tablet

Intervention Type DRUG

DWC20142

Tablet

Intervention Type DRUG

DWC20141, DWC20142

Tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult male volunteers aged 19 to 45 years
2. A sybject who has judged to be healthy by the investigator to participate in this study based on screening result
3. A subject who provided written informed consent to participate in this study and cooperative with regared to compliance with study related constraints

Exclusion Criteria

1. A subject with sign or symptoms or previously diagnosed disease of liver, digestive system, cardiovascular, kidney, respiratory, endocrinology, neurology, immune system, hematology, and psychology function or other significant disease and history.
2. A subject who shows the following result in clinical laboratory test

* AST, ALT \> 1.25 times of the upper limit of normal range
* PR ≥ 210 msec
* QRS ≥ 120 msec
* QT ≥ 500 msec
* QTcF ≥ 500 msec
3. Subject who has taken other clinical medication from another clinical trial within 3-months period prior to the first administration of the study medication.

Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes